Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | OPB-201 |
| Synonyms | |
| Therapy Description |
OPB-201 comprises autologous T-lymphocytes engineered to express a T-cell receptor (TCR) targeting PRAME, which potentially induces an anti-tumor immune response (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| OPB-201 | OPB201|OPB 201 | OPB-201 comprises autologous T-lymphocytes engineered to express a T-cell receptor (TCR) targeting PRAME, which potentially induces an anti-tumor immune response (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07664735 | Phase I | OPB-201 | A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | Recruiting | USA | 0 |